A Pharmacogenetic Approach to the Treatment of Patients With PPARG Mutations

Abstract excerpt

Loss-of-function mutations in PPARG cause familial partial lipodystrophy type 3 (FPLD3) and severe metabolic disease in many patients. Missense mutations in PPARG are present in ∼1 in 500 people. Although mutations are often binarily classified as benign or deleterious, prospective functional classification of all missense PPARG variants suggests that their impact is graded. Furthermore, in testing novel...

Topics

Share this publication in a Topic to start or enrich a Post.

• Share to Adipose Tissue and Metabolism
• Share to Metabolism, Diabetes, and Cancer
• Share to Peroxisome Proliferator-Activated Receptors